Carolinas HealthCare System

Research and Clinical Trials

Non-Hodgkin's Lymphoma 

Brief Description Principal Investigator
Primary: To determine the safety, tolerability, DLT and combination maximum tolerated dose (combination MTD) of
urelumab in combination with rituximab in subjects with relapsed/refractory B-NHL (including FL and DLBCL) or
Secondary Objectives:
1) To characterize the preliminary multidose PK profile of urelumab in combination with rituximab in subjects with
relapsed/refractory B-NHL (including FL and DLBCL) or CLL.
2) To characterize the immunogenicity of urelumab in combination with r
Ghosh, Nilanjan 
The purpose of this study for the patients with advanced stage B-cell NHL/B-AL is to test whether adding 6 injections of rituximab to standard LMB chemotherapy regimen, improves the EFS compared with LMB chemotherapy alone. Kaplan, Joel Adam 
The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL). Ghosh, Nilanjan 
To collect high quality specimens from patients with hematologic disorders and normal volunteers.
Future specimen analyses will be performed to determine the differences between sick and normal cells. Data used for these comparisons will include, but are not limited to: gene expression data, DNA, RNA, epigenetics, proteomics, metabolomics, and pathway analysys.
Avalos, Belinda Rene 
The primary objective is to evaluate the efficacy of moxetumomab pasudotox in pediatric subjects with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Oesterheld, Javier E 
To determine the maximal tolerated dose (MTD) and/or tolerable dose of escalating doses of clofarabine starting from 20mg/m2/day to 40mg/m2/day from Day 1 to Day 5 in combination with mitoxantrone 12mg/m2/day on Day 3-6 as reinduction therapy for children, adolescents and young adults with poor risk refractory/relapsed acute leukemia or high grade NHL. Oesterheld, Javier E 
To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, [Depocyt®]) and reducing the dose of anthracycline (doxorubicin) in good risk patients with the addition of rituximab to the FAB chemotherapy backbone (Immunochemotherapy). Oesterheld, Javier E 
To evaluate the efficacy of ibrutinib in combination with lenalidomide with or without rituximab by assessing the overall response in subjects with relapsed or refractory non-GCB DLBCL. Ghosh, Nilanjan 
About Carolinas HealthCare System
Who We Are
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Financial Assistance
Quality & Value Reports
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.